Still a Role for Second-Line Chemoimmunotherapy in Chronic Lymphocytic Leukemia?

Haematologica - Italy
doi 10.3324/haematol.2018.196014
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Consolidation Treatment With Lenalidomide Following Front-Line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

DNA Methylation Profiles in Chronic Lymphocytic Leukemia Patients Treated With Chemoimmunotherapy

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2019English

First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy
OncologyPharmacology
2010English

The Role of Combined Fludarabine, Cyclophosphamide and Rituximab Chemoimmunotherapy in Chronic Lymphocytic Leukemia: Current Evidence and Controversies

Therapeutic Advances in Hematology
Hematology
2016English

Disease Burden of Chemotherapy and Chemoimmunotherapy Treatment of Chronic Lymphocytic Leukemia（CLL）Patients in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

Chronic Lymphocytic Leukemia

Current Opinion in Hematology
Hematology
1998English

Chronic Lymphocytic Leukemia

Orvosi Hetilap
Medicine
2008English

Chronic Lymphocytic Leukemia

ASH Image Bank
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy